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I. PROJECT ID NUMBER, PUBLICATION  MORATORIUM INFORMATION, 
PROJECT DESCRIPTION:
This manuscript is part of a pilot effort on the part of NHI staff and the Nature publishing group to 
provide a more convenient archive for "marker papers" to be published.  These "marker papers" 
are designed to provide the users of community resource data sets with information regarding the 
status and scope of individual community resource projects.  For further information see editorial 
in September 2010 edition of Nature Genetics (Nature Genetics, 42, 729 (2010)), and the Nature 
Precedings HMP summary page.
Project ID:  46319
Publication moratorium:  One year
Emerging evidence that the gut microbiota may contribute in important ways to human health and 
disease has led us and others to hypothesize that both symbiotic and pathological relationships 
between gut microbes and their host may by key contributors to obesity and the metabolic 
complications of obesity. Our “Thrifty Microbiome Hypothesis” posits that gut microbiota play a 
key role in human energy homeostasis. Specifically, constituents of the gut microbial community 
may introduce a survival advantage to its host in times of nutrient scarcity, promoting positive 
energy balance by increasing efficiency of nutrient absorption and improving metabolic efficiency 
and energy storage. However, in the presence of excess nutrients, fat accretion and obesity may 
result, and in genetically predisposed individuals, increased fat mass may result in preferential 
abdominal obesity, ectopic fat deposition (liver, muscle), and metabolic complications of obesity 
(insulin resistance, hypertension, hyperlipidemia). Furthermore, in the presence of excess 
nutrients, a pathological transition of the gut microbial community may occur, causing leakage of 
bacterial products into the intestinal lymphatics and portal circulation, thereby inducing an 



































This pathological transition and the extent to which antimicrobial leakage occurs and causes 
inflammatory and other maladaptive sequelae of obesity may also be influenced by host factors, 
including genetics. In the proposed study, we will directly test the Thrifty Mirobiome Hypothesis 
by performing detailed genomic and functional assessment of gut microbial communities in 
intensively phenotyped and genotyped human subjects before and after intentional manipulation of 
the gut microbiome. To address this hypothesis, we will enroll three age- and sex-matched groups 
from the Old Order Amish: (i) 50 obese subjects (BMI > 30 kg/m2) with one or more 
dysmetabolic manifestations (malignant obesity), (ii) 50 obese subjects (BMI > 30 kg/m2) without 
any dysmetabolic manifestations  (benign obesity), and (iii) 50 nonobese subjects (BMI < 25 
kg/m2) without any features of the metabolic syndrome and characterize the architecture of the gut 
microbiota from the subjects enrolled in this study by high-throughput sequencing of 16S rRNA 
genes. These studies will provide a deeper understanding of the role of gut microbes in terms of 
‘who’s there?’, ‘what are they doing?’, and ‘how are they influencing host energy homeostasis, 
obesity and its metabolic complications?’
II. DATA QUALITY:  
Sequencing quality control: Through the use of automated reports, the LIMS at the Genomic 
Resource Center (GRC) at the Institute for Genome Sciences enables staff to monitor data quality 
trends in real time and quickly identify problems. Because each sample, plate, and well is tracked 
through each of the pipelines, and quality control tests are performed at key steps, problems that 
occur can be rapidly isolated and the cause identified, tested, and resolved. These reports are 
monitored daily by the GRC Directors and provide data about sequencing success, read length, and 
sequence quality by sequencer instrument, sequencing run, project, library, operator, and date. 
When the GRC detects a potential problem in one of the sequencing pipelines, these reports are 
used  to  identify  potential  causes.  Usually  the  cause  can  be  narrowed to  a  small  number  of 
possibilities within minutes. Consistency is essential to the efficient operation of a high-throughput 
genomics laboratory. To ensure this consistency, all activities within the GRC are based on tested 
and approved Standard Operating Procedures. These SOPs are written in a standardized format 
and include detailed instructions for the performance of each laboratory or bioinformatics protocol. 
New or modified SOPs undergo review and scientific approval by the assigned reviewer and are 
approved for publication to the IGS internal web site and use by the GRC Directors. At minimum, 
each SOP is reviewed annually by the GRC Scientific Director.
454 pyrosequencing of  barcoded 16S rRNA genes:  The V1-V2 regions  of  16S rRNA genes 
were/will be sequenced using Roche/454 FLX and Titanium chemistries. To pass quality control a 
sequence read (a) included a perfect match to the sequence tag (barcode) and the 16S rRNA gene 
primer; (b) was at least 300 bp in length; (c) had no more than two undetermined bases; and (d) 



































NAST. An average ~4,000 reads were/will be generated per sample. The depth of coverage for 
each community is sufficient to detect taxa that constitute ~0.1% of the community.
Metadata quality control: Old Order Amish subjects are recruited by trained personnel at the 
Amish Research Clinic in Lancaster, PA. Pertinent medical history, height, weight, and waist 
circumference is obtained using established protocols and quality assurance methods. Fasting 
blood is drawn and serum glucose and lipid levels are measured (Quest Diagnostics, Horsham, 
PA). Vitamins and supplements were discontinued for at least 14 days prior to two fecal 
collections, which were obtained 3 to 24 months apart from each research subject. The fecal 
sample is immediately suspended in RNALater for subsequent processing and 16S sequence 
analysis. 
We will comprehensively capture metadata associated with our microbiome samples to support 
comparisons between these samples based on attributes such as patient disease history, collection 
procedures or site of infection. Unfortunately, a universally recognized standard describing 
microbiome metadata has yet to emerge. To ameliorate this we will operate in close collaboration 
with the larger metagenomic community on development of this standard. Currently the best 
contender for a standard metadata description is the Minimum Information about Metagenome 
Sequence (MIMS) which has been crafted by the Genome Standards Consortium (Field et al., 
2008). We will work to promote coordination for metadata description through the GSC, as well as 
the to-be-funded Data Analysis and Coordination Center (DACC) for the HMP; we consider these 
bodies to be the most significant focal points for data standards and integration. 
III. DATA ANALYSIS AND PUBLICATION PLANS:  
Following trimming of primer and barcode sequences, binning by sample, and removal of reads 
containing ambiguous bases, 16S sequencing data will be analyzed using both phylogenetic 
binning and operational taxonomical unit (OTU)-based approaches. The former approach allows 
us to generate, for each sample, the ratio of the two dominant phyla in the gut microbiome 
(Bacteroides:Firmicutes) and also to identify family- and genus-level taxa whose prevalence in the 
human gut may correlate with obesity. Using our OTU-based analysis, we will generate trees 
showing the relatedness of samples to each other and also to calculate a measure of the bacterial 
diversity present in each sample (Shannon index). A major focus of our analysis will be to 
examine potential correlations between Bacteroides:Firmicutes ratios or Shannon indices and 
characteristics of the human host, including the existence of single nucleotide polymorphisms 



































A manuscript describing the results of these analyses is currently in preparation and we expect to 
submit it in the fall of 2010.
IV. DATA RELEASE PLAN:  
Release of clinical data to a controlled access site specified by the NIH.  We will work with the 
HMP Program Officers and other HMP awardees to establish the appropriate guidelines for release 
of clinical data to a controlled access site specified by the NIH. We are aware of the potential 
sensitivities in making clinical data available and we are willing to participate in any discussions 
related to this topic to ensure that we strike the appropriate balance between respecting patient 
confidentiality and making any relevant clinical data that will aid in interpretation of metagenomic 
datasets available to the investigators who need access to this information. 
Release of sequence read and trace data or the equivalent for new technologies. We will deposit 
16S rRNA gene sequences in GenBank, using the standard batch upload procedure. One common 
issue with environmental samples of 16S rRNA is that metadata about the environment is lost, 
which can limit reusability of the sequences in further analyses by other investigators. We will 
address this issue by including within the “source” feature an “isolation_source” descriptor that 
stores the string “Homo sapiens fecal sample”, along with a coded patient id, health status and 
sample collection data in a comma-delimited format. This will allow automated parsing tools to 
assign each sequence to the correct sample. Deposition in GenBank will also ensure inclusion of 
the sequences in the Ribosomal Database Project at http://rdp.cme.msu.edu, which automatically 
compiles sequences from GenBank on a monthly basis. 
In collaboration with HMP Program Officers, we will develop a plan for release of whole 
microbial community shotgun sequencing data generated under this project. We would suggest 
that a plan be devised that would make this data available to the scientific community as quickly as 
possible (e.g., weekly downloads of sequences to the Trace Archive or Short Read Archive, as 
appropriate, and monthly downloads of assembled data), while at the same time respecting the 
priorities of the investigators carrying out the work to perform an initial analysis of these data. A 
combined assembly of all datasets will be submitted to GenBank as a Whole Genome Shotgun 
project, containing all contiguous sequences. This central page will contain links to an assembly of 
each individual fecal/biopsy microbiome dataset (deposited as distinct projects) and the raw 
sequencing reads (deposited in the NCBI Short Read Archive). Deposited sequences will be 
annotated according to site of sampling (fecal samples/location of biopsies, etc.); DNA extraction 
method, sequencing method, predicted functions (COG, KEGG, InterPro assignments), predicted 



































Release of any other type of data to characterize the microbiome being studies. The Amish Obesity 
Project Database (AOPD) repository will be a short-term resting place for all data generated in this 
project, and will be hosted and maintained at UMSOM. Upon advice from the HMP Program 
Officers, this data resource will be moved to the to-be created HMP DACC, for longer term 
maintenance and better public accessibility, when appropriate. Release of metadata associated with 
sequence traces or other types of data. We will work with the HMP Program Officers and other 
HMP awardees to establish the appropriate guidelines for release of metadata. We can deposit 
metadata in the Short Read Archive, or house this information on our project website. We would 
recommend that all HMP awardees work with the HMP Program Officers to develop a set of 
standards related to metadata to facilitate comparisons between datasets.  
Release of analysis performed by the awardee.  It is our intention to use scientific publications as 
the primary means of releasing the analyses that will be performed in the course of these studies. 
V. CONTACT PERSON: 
Dr. Claire M. Fraser-Liggett, University of Maryland Baltimore, 410-706-3879, 
cmfraser@som.umaryland.edu (details regarding 16S sequencing and microbiome analyses)
Dr. Alan R. Shuldiner, University of Maryland Baltimore, 410-706-1623
ashuldin@medicine.umaryland.edu (details regarding subject recruitment, characteristics and 
phenotyping)
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